BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Zyleris PharmaTech Release: Throughput Formulation Screening Service for Topical and Transdermal Drug Development


6/17/2010 10:22:32 AM

Zyleris PharmaTech (www.Zyleris.com) has announced today the launch of its high-throughput formulation screening service for topical and transdermal drug development based on the company’s innovative experimentation technology.

Zyleris’ technology is designed to transform topical and transdermal drug development. The technology utilizes Franz Cell principle in a high-throughput fashion, which is at least 20x faster than present industrial standard Franz Cell technology and lowering costs up to 90% per formulation. It also offers higher detection sensitivity than Franz Cell technology due to its unique design. The main technical features include easy-to-use compact design, flexible diffusion area suitable for percutaneous absorption and permeation studies, all glass and Teflon construction, and an easy sample collection mechanism.

"Many researchers tell us that identifying suitable topical and transdermal formulations for clinical development is often quite tedious and expensive. Due to the limitations of current Franz Cell technology, such as low speed and high cost, only a limited number of candidate formulations can reasonably be screened and evaluated. Researchers always wonder: is the formulation slated for clinical development really best possible one to move forward? Thus, the market is ripe for a high speed and yet cost efficient solution. Our technology fills this gap by offering the best of both worlds - speed associated with high-throughput technology and yet result compatibility with industrial standard Franz Cell technology. We understood that from the beginning and developed a truly innovative solution for this challenge and brought speed and cost efficiency to the process." says Zyleris founder and CEO, Jerry Zhang, PhD.

Zyleris’ objective is to continue developing innovative solutions, technologies, and services for topical and transdermal drug research and development.

About Zyleris PharmaTech

Founded in 2009 and headquartered in Chicago, IL, U.S.A, Zyleris PharmaTech is a contract research service company delivering best-in-class high-throughput experimentation technologies and services for accelerating topical and transdermal drug R&D process. For more information about the company, visit www.zyleris.com.

Contact Information

Jerry Zhang Phone: 847-604-8474 Email: jerryzhang@zyleris.com



Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES